TWST Newsletter

Give us your email address and receive the TWST Newsletter.


Subscribe to TWST

The Wall Street Transcript is a completely unique resource for investors and business researchers. Thousands of in-depth interviews with CEOs, Industry Analysts and Professional Money Managers going back 10 years.

To obtain a copy of a TWST issue/report order online or call (212) 952-7433 .

SUBSCRIBE

Search TWST Online

Search by ticker:
or Sector:
Search by keyword:

VP Of Mahindra Satyam Life Sciences Business Discusses Future Trends For The Software Giant; Discover His Goals For The Company

October 5, 2010 - The Wall Street Transcript has just published Health Care IT Report offering a timely review of the Healthcare Information Services sector. This Special Report contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. Please find an excerpt below.

View Details of This Special Report

Recent Wall Street Transcript Special Reports.

Vivek Ghai heads Mahindra Satyam's health care and life sciences business in the North America market. Additionally, he also anchors the global strategy for Mahindra Satyam's health care and life sciences practice, developing plans, investing in vertical-specific solutions, competencies and centers of excellence, and building alliance partnerships. As member of the leadership council, the highest steering group at Mahindra Satyam, Mr. Ghai is also responsible for establishing strategic direction and deploying operating plans to achieve the long-term goals. With more than 20 years of experience in the information technology industry, Mr. Ghai has served in a variety of leadership roles, setting up and leading globally distributed service delivery infrastructures, establishing and leading large customer service relationships, and leading large business portfolios with P&L responsibility. Prior to joining Mahindra Satyam, he spent nine years as an entrepreneur, and Founder and CEO of a very successful information technology company in India before selling it in 2001. Mr. Ghai is an alumnus of the Indian Institute of Technology, Bombay, and he holds an MBA from Mumbai University.

TWST: Let's start with a broad overview and history of Mahindra Satyam.

Mr. Ghai: Satyam (SAY)and now Mahindra Satyam have been in the business of providing technology and enterprise solutions for over 20 years now. We have somewhere in the region of 380-plus customers in 30 countries worldwide. We provide enterprise business solutions typically focused on information technology to our customers; we also provide IT infrastructure services, engineering services and business process outsourcing services. Within the enterprise services, we also provide services such as application development and maintenance, ERP implementation, business intelligence, data warehousing solutions, so on and so forth.

TWST: When did you add health care and life sciences to your services roster? What prompted the move to those areas?

Mr. Ghai: Health care and life sciences, as it is represented today within Mahindra Satyam, constitutes three subverticals. There is the life sciences vertical, which is the pharmaceutical, biotech and medical devices segment; then there is the health insurance sector and the health care provider sector, which are typically hospitals and clinics, etc. If you look at our history, these three entities actually evolved independently. Life sciences and health insurance broadly date back 10-plus years, and some of our current relationships with our customers date back just as long. Actually, health insurance originally existed as a part of our broader insurance vertical. The health care provider segment within the United States market was an area of focus that we initiated about two years ago. Last year, recognizing the fact that there are a whole lot of changes in the health care sector, both from regulatory perspective and business environment perspective, we made a decision to put these together under the broader umbrellas of health care and life sciences.

TWST: Do you offer off-the-shelf products and services or solely custom solutions?

Mr. Ghai: It's usually a combination. Mahindra Satyam is not in the business of developing products, but what we typically do is take products that are available in the market, build robust methodologies around it, train our people in the subject matter expertise as well as the technical aspects around the product, and develop a process framework to deliver a solution to the customer. Take a recent example of our HIPAA 5010 migration solutions. We develop methodologies, and we bring together our industry knowledge and our people. We combine this with an existing product and then offer it as a solution to the customer that helps them make this transition faster, better, cheaper, and enable them to achieve their business goals. But usually what we offer are solutions that might be preconfigured but also customizable to a specific customer requirement. On the other hand, our solutions could be absolutely a custom-developed product, so we offer both flavors. But we are typically not in the business of developing products; we usually work with product companies.

TWST: Is iDecisions an analytic product?

Mr. Ghai: Yes, iDecisions is an analytics product, but even more than a product, it's actually a framework. That's one example where we do have a custom product plus framework. When we offer an iDecisions framework, it is the product plus an industry implementation of the product. It could be in the sales and marketing area in pharmaceutical, or it could be in clinical analytics and offer meaningful use in hospitals. But iDecisions is a product offered along with a framework.

The remainder of this 39 page Health Care IT Report can be immediately viewed by purchasing online.


The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This Special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

For Information on subscribing to The Wall Street Transcript, please call 800/246-7673